Clinical Trial Update: Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating daclizumab for non-infectious sight-threatening uveitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• Daclizumab (daclizumab)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Uveitis | Phase 2 | Status: COMPLETED